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 Porousbiodegradable polymer scaffolds are widely utilized for bone tissue 
engineering, but are not osteoconductive like calcium phosphate scaffolds. 
We combine indirect solid freeform fabrication (SFF), ex vivo gene therapy, 
with biomineral coating to compare the effect of biomineral coating on bone 
regeneration for Poly ( L -lactic acid) (PLLA) and Poly (ε-caprolactone) (PCL) 
scaffolds with the same porous architecture. Scanning electron microscope 
(SEM) and micro-computed tomography (µ-CT) demonstrate PLLA and PCL 
scaffolds have the same porous architecture and are completely coated. All 
scaffolds are seeded with human gingival fi broblasts (HGF) transduced with 
adenovirus encoded with either bone morphogenetic protein 7 (BMP-7) or 
green fl uorescent protein (GFP), and implanted into mice subcutaneously 
for 3 and 10 weeks. Only scaffolds with BMP-7 transduced HGFs show 
mineralized tissue formation. At 3 weeks some blood vessel-like structures 
are observed in coated PLLA and PCL scaffolds, but there is no signifi cant 
difference in bone ingrowth between the coated and uncoated scaffolds for 
either PLLA or PCL. At 10 weeks, however, coated scaffolds (both PLLA and 
PCL) have signifi cantly more bone ingrowth than uncoated scaffolds, which 
have more fi brous tissue. Coated PLLA scaffolds have improved mechanical 
properties compared with uncoated PLLA scaffolds due to increased bone 
ingrowth. 
shapes and support mechanical loads. 
Furthermore, they should enhance tissue 
ingrowth and degrade in conjunction with 
tissue healing. [ 1 ] To achieve these goals, 
computer-aided design (CAD) and solid 
freeform fabrication (SFF) or 3D printing 
techniques have been utilized to fabri-
cate biodegradable scaffolds from various 
materials and in various shapes. [ 2–5 ] SFF 
scaffolds have well controlled and inter-
connected pores to enhance cell migration 
as well as superior mechanical properties 
for load-bearing applications compared 
with conventional scaffolds, made from 
processes such as porogen leaching. [ 6–9 ] 
 FDA-approved biodegradable poly 
(α-hydroxy esters), including poly ( L -lactic 
acid) (PLLA) and poly(ε-caprolactone) 
(PCL), have been widely used for ortho-
pedic implants, tissue engineering scaf-
folds, and drug delivery vehicles. [ 10–13 ] 
It is well known that both materials 
degrade by hydrolysis, but PCL has a 
more hydrophobic surface and slower 
degradation than PLLA. [ 14,15 ] In spite of 
the wide usage of these polymers, one of 
their disadvantages is poor osteoconduc-
tivity compared with scaffolds made of hydroxyapatite (HA) 
and tricalcium phosphate (TCP). 
 Biomineral coating of substrate surfaces using simulated 
body fl uid (SBF), which contains similar ion components to 
human blood, is a promising technique to improve the osteo-
conductivity of bone tissue engineering scaffolds. [ 16–18 ] In this 
 1.  Introduction 
 Numerous scaffolds have been investigated for reconstructing 
bone defects using tissue engineering. Ideal bone tissue engi-
neering scaffolds should be fabricated to fi t complex defect 
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technique, biomaterials are immersed in SBF, and then nano-
structured carbonate apatite minerals, similar to the mineral 
component of bone tissue, precipitate on the biomaterial sur-
faces. [ 17,19,20 ] This method has successfully been applied to var-
ious biomaterials including metals, [ 21,22 ] polymers, [ 19,23,24 ] and 
the composites of polymers and HA or other calcium phosphate 
minerals [ 23,25,26 ] to enhance bone cell function and bone tissue 
regeneration. Previous studies show promising effects of 
biomineral coating including enhanced bone ingrowth and 
more direct bone surface contact on mineral-coated titanium 
implants compared to uncoated titanium implants. [ 21,22,27 ] A 
few coated biodegradable substrates, such as PLGA scaffolds 
and microspheres, have also shown improved bone formation 
 in vivo . [ 28,29 ] 
 Although many previous studies have demonstrated a posi-
tive effect of apatite-coatings on bone tissue formation, other 
studies have shown less benefi cial effects of mineral coat-
ings. Specifi cally, some studies found a diminished effect of 
biomineral coatings on bone formation and fi brovascular tis-
sues, with increased numbers of body giant cells in vivo using 
porous poly(ε-caprolactone- co - L -lactide) scaffolds, SFF PCL 
scaffolds, or SFF titanium scaffolds. [ 23,24,30 ] In addition, min-
eral-coated scaffolds formed via salt-leaching techniques tend 
to have less open pore structures that limit effective coating 
at the center of the scaffolds, resulting in poor bone ingrowth 
towards the center of the scaffolds. [ 31 ] Taken together, these 
studies suggest a potentially important effect of biomineral-
coated biodegradable scaffolds on  in vivo bone formation, but 
the effect of scaffold substrate material and porous architec-
ture morphology on the effi cacy of biomaterial coating is still 
not well understood. 
 In order to develop ideal scaffolds for bone regeneration, 
it is necessary to understand not only the effect of biomin-
eral coatings on biodegradable scaffolds but also the effect of 
biomineral-coated scaffolds on different substrate materials 
with the same porous architecture. To address these needs, 
we combined SFF scaffolds with biomineral coating using two 
types of biodegradable polymers, PLLA and PCL. We previously 
characterized this coating on design 3D printed scaffolds with 
interconnected pore structures. [ 32 ] In the present study, bone 
tissue was regenerated in ectopic site utilizing bone morpho-
genetic protein 7 (BMP-7)-transduced human gingival fi bro-
blasts (HGFs) delivered from the scaffolds, a commonly used 
model for bone tissue engineering. [ 33–36 ] We hypothesized that 
biomineral-coated SFF scaffolds would have improved bone 
ingrowth over uncoated scaffolds seeded with BMP-7-trans-
duced HGFs, and that the different degradation characteristics 
of PLLA and PCL would also infl uence bone ingrowth. PLLA 
and PCL scaffolds with the same designed porous architecture 
were fabricated using indirect SFF and coated with a modifi ed 
SBF technique. The fabricated scaffolds were characterized 
using micro-computed tomography (µ-CT) and scanning elec-
tron microscope (SEM) techniques. Subsequently, the scaffolds 
were seeded with either BMP-7 or green fl uorescent protein 
(GFP)-transduced HGFs. Finally scaffold/cell constructs were 
subcutaneously implanted into mice for 3 and 10 weeks. The 
regenerated bone tissue along with base scaffold materials was 
characterized using µ-CT, histology. and mechanical testing 
techniques. 
 2.  Results 
 2.1.  Architecture and Morphology of Coated and Uncoated 
Scaffolds 
 The gross images of the fabricated scaffolds are shown in 
 Figure  1 a–d provided from our previous publication with 
permission. [ 32 ] The uncoated PLLA and PCL scaffolds had sim-
ilar 3D architecture and surface morphology, which became 
less transparent after mineral coating. Microscopic architec-
ture, including pore interconnection, of the uncoated PLLA 
and PCL scaffolds was analyzed using µ-CT (Figure  1 f,h). Pore 
size, strut size, volume, surface area, and surface to volume 
ratio were similar between the uncoated PLLA and PCL scaf-
folds, demonstrating the scaffolds had the same architecture 
( Table  1 ). µ-CT data also showed the existence of mineral 
layers inside the coated scaffold architectures (Figure  1 e,g). A 
smoother surface was observed on the uncoated PLLA and PCL 
scaffolds (Figure  1 j,l,n,p), while the coated PLLA and PCL scaf-
folds had a rougher surface (Figure  1 i,k,m,o). Nanoscale plate-
like crystalline structures were observed in the mineral coating 
on both coated PLLA and PCL scaffolds ( Figure  2 a,b) provided 
from our previous publication with permission. [ 32 ] Analysis of 
the biomineral composition by X-ray energy-dispersive spec-
troscopy (XEDS) showed that the mineral was composed pri-
marily of calcium and phosphorous with a Ca/P ratio of 1.58 
for the coated PLLA scaffold (Figure  2 c) and 1.56 for the coated 
PCL scaffold (Figure  2 d), which are both in the range of biolog-
ical apatites. Biomineral crystallinity, obtained after dissolving 
the coated PLLA and PCL scaffolds in chloroform, showed that 
the coated PLLA and PCL scaffolds had mineral crystal peaks 
similar to those of HA (Figure  2 e,f). These data demonstrate 
growth of bone-like minerals on the scaffold surfaces. 
 2.2.  Bone Formation in Implanted Scaffolds 
 µ-CT cross-section images of 3 and 10 weeks post subcuta-
neous implantations are shown in  Figure  3 . The white color 
indicates either regenerated bone tissue or biomineral coating 
on the scaffolds, while both PLLA and PCL parts were radiolu-
cent. The scaffolds with BMP-7-transduced HGFs were covered 
by bone-like tissue and a mineralized shell after 3 and 10 weeks 
implantation as shown on µ-CT images (Figure  3 a,c,e,g,i,k,m,o), 
while scaffolds with GFP- transduced HGFs did not show bone 
ingrowth or have a mineralized shell (Figure  3 b,d,f,h,j,l,n,p). 
The coated scaffolds with GFP-transduced HGFs showed 
biomineral layers on the scaffold surfaces (Figure  3 b,d,f,h) at 
3 and 10 weeks but no gross evidence of bone formation based 
on morphology. 
 Overall bone ingrowth for the scaffolds with BMP-7-trans-
duced HGFs was calculated as the amount of bone in the 
defi ned global Region of Interest (Global ROI; see Experi-
mental Section). In the µ-CT images, generated bone tissues 
have higher density than initially coated biomineral layers. To 
investigate bone ingrowth into the scaffolds without initial min-
eral coatings, a ROI with threshold value 1100HU was applied, 
and the amount of mineral from µ-CT of the preimplanted scaf-
folds was subtracted from total mineral of the post-implanted 
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scaffolds. As shown in  Figure  4 a–d, there is little bone ingrowth 
into the scaffold constructs at 3 weeks, and no statistical differ-
ence was found between the groups ( Figure  5 a). At 10 weeks, 
the coated scaffolds had more advanced bone ingrowth than 
the uncoated scaffolds, and the bone formation followed the 
architecture of the scaffolds (Figure  4 e,g). The uncoated scaf-
folds showed less bone ingrowth in the scaffolds (Figure  4 f,h) 
at the same time point. Statistical analysis confi rmed that 
coated PLLA and PCL scaffolds had signifi cantly greater bone 
ingrowth than the uncoated PLLA and PCL scaffolds (Figure  5 a, 
indicated by *). In addition, bone ingrowth of the coated PLLA 
scaffolds was signifi cantly higher than that of the uncoated PCL 
scaffolds (Figure  5 a, indicated by **), indicating that mineral 
coating may enhance bone ingrowth over the base material 
difference. 
 To further understand bone ingrowth, concentric rings of 
ROIs (Outermost: ConROI-5, Innermost: ConROI-1, Experi-
mental Section) was applied to the scaffolds at 10 weeks 
implantation (Figure  5 b–e) and the preimplanted scaffolds 
(Figure  5 f). The coated PLLA showed signifi cantly more bone 
ingrowth than the uncoated PLLA from ConROI-5 to ConROI-2 
(Figure  5 b, indicated by +), while the coated PCL showed sig-
nifi cantly more bone ingrowth than the uncoated PCL from 
ConROI-4 to ConROI-1 (Figure  5 c, indicated by ++). The 
coated PLLA showed more bone ingrowth than the coated 
PCL at ConROI-5 (Figure  5 d, indicated by +++), while there 
is no signifi cant difference between the uncoated PLLA and 
the uncoated PCL (Figure  5 e). Although mineral layers were 
observed over the entire surface of the coated PLLA and PCL 
scaffolds, the coated PLLA has more initial mineral coating 
than the coated PCL at ConROI-5, and ConROI-4 (Figure  5 f, 
indicated by #). 
 2.3.  Histology Data 
 Harvested scaffolds with BMP-7-transduced HGFs were 
evaluated using histological techniques, H&E ( Figure  6 ) and 
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 Figure 1.  Pictures, µ-CT images, and ESEM images of coated PLLA (a,e,i,m), uncoated PLLA (b,f,j,n), coated PCL (c,g,k,o), and uncoated PCL (d,h,l,p), 
respectively. µ-CT images confi rm that mineral layer covered the surface of both PLLA and PCL scaffolds (e,g). ESEM images show the rough surface 
of the coated PLLA and PCL scaffolds with low (i,k) and high (m,o) magnifi cations, while the relatively smooth surface of the uncoated PLLA and PCL 
scaffolds with low (j,l) and high (n,p) magnifi cations. Images were provided from our previous study with permission. [ 32 ] 
 Table 1.  Fabricated uncoated PLLA and PCL scaffolds. 
Pore size 
[mm]
Strut size 
[mm]
Volume 
[mm 3 ]
Surface 
[mm 2 ]
Surface/Volume
PLLA Scaffold 0.60 ± 0.03 0.67 ± 0.03 33.26 ± 2.19 187.13 ± 13.75 5.63 ± 0.20
PCL Scaffold 0.61 ± 0.04 0.67 ± 0.03 30.97 ± 1.29 182.22 ± 10.82 5.88 ± 0.13
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Masson’s Trichrome (Figure  1 , Supporting Information). PLLA 
and PCL materials were removed by chloroform, and became 
transparent in the images (indicated by @). H&E staining 
showed little bone-like tissue formation in the pores of the 
coated and uncoated PLLA and PCL scaffolds at 3 weeks (Figure 
 6 a,b,e,f). However, the pores of the coated scaffolds contained 
blood vessel-like tissues, which may be a precursor of bone 
ingrowth (Figure  6 a,e; green arrows). In contrast, the uncoated 
scaffolds showed few blood vessels (Figure  6 b,f). Subsequent 10 
week histology of the coated PLLA and PCL scaffolds showed 
developing bone-like tissue containing marrow in the pores fol-
lowing the pore architecture of the scaffolds (Figure  6 c,g). The 
uncoated PLLA and PCL did not have much bone ingrowth at 
10 weeks and contained fi brous-like or fat-like tissues in the 
pores (Figure  6 d,h). Masson's Trichrome staining also showed 
little bone-like tissue in the pores of coated and uncoated PLLA 
and PCL scaffolds at 3 weeks (Figure  2 a,b,e,f, Supporting 
Information). At 10 weeks, however, the coated PLLA and PCL 
scaffolds had well-developed bone tissue containing osteoid 
(Figure  3 c,g, Supporting Information), indicating active deposi-
tion of bone mineral in comparison to the uncoated scaffolds. 
 To investigate the boundary of regenerated bone tissue and 
initial biomineral coating, the scaffolds with BMP-7-transduced 
HGFs were embedded in epoxy and sectioned without decalci-
fying tissues and removing scaffolds ( Figure  7 ). Initial mineral 
coating and regenerated bone tissue was seen on the coated 
PLLA scaffolds (Figure  7 a,e) and the coated PCL scaffolds 
(Figure  7 j,n). Initial mineral coatings show random and less 
aligned morphology (solid orange arrow) and regenerated bone 
tissue, while regenerated bone tissue shows more packed and 
aligned structure (open orange arrow). There was poor bone 
tissue integration into the mineral coating at 3 weeks (Figure  7 , 
yellow box area (b,k)) as both µ-CT and histological data demon-
strate, while bone tissue had more direct bonding on the mineral 
coating at 10 weeks (Figure  7 , yellow box area, left (f,o), and right 
(g,p). The uncoated PLLA and PCL scaffolds had trabecular-like 
tissue adjacent to, but not directly integrated to the scaffold sur-
face (Figure  7 c,d,l,m), in contrast to the coated scaffold surfaces 
at 3 weeks. Bone tissue was still lining the scaffold surface (open 
green arrow) but not integrated into the polymer (solid green 
arrow) at 10 weeks (Figure  7 h,i,q,r), again in contrast to the more 
intimate bone contact on the coated scaffold surfaces. 
 2.4.  Mechanical Testing of Scaffolds with and Without 
Bone Tissue 
 Effective scaffold elastic moduli for the constructs with BMP-
7-transduced HGFs were determined at 3 and 10 weeks 
( Figure  8 a). The moduli of both coated and uncoated PLLA scaf-
folds decreased after scaffold implantation from 0 to 3 weeks, 
likely due to polymer degradation ( p = 0.046 and 0.001, respec-
tively, indicated by #). The moduli of the coated PLLA scaffolds 
signifi cantly increased from 3 to 10 weeks ( p = 0.046, indicated 
by ##); however, the moduli of uncoated PLLA scaffolds did not 
signifi cantly increase ( p = 0.590). Uncoated PCL scaffolds also 
had signifi cantly increased elastic moduli from 3 to 10 weeks 
( p = 0.028, indicated by ##). Although the coated PCL scaffolds 
did not have a signifi cant improvement of elastic moduli, the  p 
value was close to the signifi cant level ( p = 0.073). 
 Elastic moduli of the scaffolds with GFP-transduced HGFs 
were also tested (Figure  8 b). Only the uncoated PLLA scaffold 
showed a signifi cant decrease of moduli from 0 to 3 weeks 
(indicated by +). Moduli of the coated and the uncoated PLLA 
scaffold increased from 3 to 10 weeks, but not signifi cantly, 
perhaps due to more fi brous tissue formation resulting from 
polymer degradation. The coated and uncoated PCL scaffolds 
show constant moduli throughout the study period indicating 
little degradation of PCL during this study period. 
 3.  Discussion 
 Computer-aided tissue engineering utilizing 3D rapid 
prototyping/3D printing techniques has been used to fabricate 
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 Figure 2.  SEM images, XEDS, and XRD data of the coated PLLA (a,c,e) 
and PCL (b,d,f) scaffolds. SEM images show that nucleated bone-like 
mineral structures on the coated PLLA (a) and PCL scaffolds (b). XEDS 
data confi rmed that existence of calcium and phosphorous peaks (c,d). 
XRD data of the mineral- coated scaffolds were obtained after dissolving 
them in chloroform, coated PLLA (e) and coated PCL (f). Mineral peaks 
refl ecting HAP pattern were shown. Data were provided from our pre-
vious study with permission. [ 32 ] 
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scaffolds with precisely controlled architectures matching ana-
tomical shapes and achieving desired properties for clinical 
applications. These controlled scaffold architectures have been 
shown to signifi cantly affect both bone formation and scaf-
fold degradation  in vivo . [ 37–40 ] In addition, modifi ed simulated 
body fl uids (mSBF) have been utilized to grow mineral layers 
on biodegradable materials, [ 28,41,42 ] and SFF scaffolds. [ 43,44 ] 
Although some research has investigated the infl uence of 
biomineral-coated PLLA and PCL scaffolds on bone regenera-
tion independently, [ 45,46 ] no study has successfully investigated 
the effects of biomineral coatings and scaffold base materials on 
bone regeneration using identical scaffold porous architectures. 
Adv. Healthcare Mater. 2015, 4, 621–632
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 Figure 3.  µ-CT cross sectional images of implanted scaffolds with adenovirus BMP-7 or adenovirus GFP-transduced HGFs at 3 and 10 weeks. The 
scaffolds with BMP-7 groups were covered with bony shells (a,c,e,g,i,k,m,o), while the scaffolds with GFP groups did not show any bony shells 
(b,d,f,h,j,l,n,p). Coated PLLA and PCL with GFP-transduced scaffolds showed the existence of mineral coating on the scaffold surfaces (b,d,f,h). 
Uncoated PLLA and PCL with GFP-transduced scaffolds did not appear on the µ-CT images due to low intensity of polymers and no mineralized 
tissues (j,l,n,p).
 Figure 4.  Bone ingrowth into coated PLLA (a,e), uncoated PLLA (b,f), coated PCL (e,g), and uncoated PCL (d,h) scaffolds at 3 and 10 weeks implanta-
tion. There was a little bone ingrwoth in the all scaffolds at 3 weeks (a–d). At 10 weeks, the coated PLLA and PCL scaffolds displayed advanced bone 
ingrowth followed the designed architectures (e,h) compared to the poor bone ingrowth of their respective scaffolds (f,h).
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Therefore, we developed biomineral-coated PLLA and PCL 
porous scaffolds combining indirect SFF and mSBF techniques 
to test the effect of mineral coating and scaffold base materials 
on  in vivo bone formation. 
 The fabricated PLLA and PCL scaffolds were confi rmed 
to have identical structure and orthogonally interconnected 
channel pores (Figure  1 , Table  1 ), which agreed with our 
previous SFF scaffold studies including PLLA and PCL 
Adv. Healthcare Mater. 2015, 4, 621–632
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 Figure 5.  Calculated bone ingrowth (a) in Global ROI at 3 and 10 weeks implantations ( N = 8). There is no signifi cant difference between the scaffolds at 
3 weeks. However, the coated PLLA and PCL scaffolds showed signifi cantly more bone ingrowth than the uncoated PLLA and PCL scaffolds at 10 weeks 
(indicated by *). In addition, the coated PLLA scaffolds had signifi cantly more bone ingrowth than the uncoated PCL scaffolds at 10 weeks (indicated by 
**). Concentric ROI was applied to scaffolds at 10 weeks implantation (b–e) and preimplanted scaffolds (f) ( N = 8). Coated PLLA showed signifi cantly 
more bone ingrowth than uncoated PLLA with ConROI-5 to -2 (b), while coated PCL showed signifi cantly more bone ingrowth than uncoated PCL 
with ConROI-4 to -1 (c) (indicated by + and ++, respectively). Coated PLLA showed more bone ingrowth at ConROI-5 than coated PCL (d) (indicated 
by +++), while there is no signifi cant difference between uncoated PLLA and uncoated PCL (e). Coated PLLA has more initial mineral coating than 
coated PCL at ConROI-5, and -4 (f) (indicated by #).
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scaffolds. [ 7,38,39 ] The fact that biomineral layers coved the entire 
surface of the scaffolds (Figure  1 ) supports the premise that fully 
designed interconnected channels of the fabricated scaffolds 
allowed the mSBF solution to infi ltrate into the center of the 
scaffolds. The coated mineral layers have plate-like morphology, 
which is similar to human bone tissue, and consistent with bio-
mimetic coating formed in previous studies indicating that the 
mineral formed in this study is the poorly crystalline, carbonate 
substituted, and calcium-defi cient HA phase. [ 19,28,44 ] XEDS data 
showed calcium and phosphate peaks on the coated mineral, 
which indicated both coated PLLA and PCL scaffolds had sim-
ilar nucleated mineral and Ca/P ratios close to that of HA. [ 19,41 ] 
 Ectopic bone formation has been reproducibly generated 
by delivery of BMP-7-transduced HGFs. [ 34,47 ] Bone shells were 
formed surrounding the scaffolds containing HGF trans-
duced with adenovirus BMP-7, similar to our previous scaf-
fold studies, [ 36–38,48 ] whereas control groups with adenovirus 
GFP-transduced HGFs showed no bone shell formation 
(Figure  3 ). The result suggests that bone tissue is mainly induced 
by secreted BMP-7 proteins, not by biomineral coatings or HGF 
alone. This is consistent with previous studies demonstrating 
that biomineral coatings are osteoconductive, but not osteoin-
ductive, that is capable of inducing ectopic bone formation. [ 49 ] 
 Interestingly, the signifi cant effect of biomineral coatings 
on bone formation was found at 10 week implantation, but not 
at 3 weeks (Figure  4 and  5 a). Previous paper suggest that host 
mesenchymal stem cells are primarily involved in bone forma-
tion, and there is less contribution from transduced cells. [ 34,47 ] 
In addition, most bone formation started outside of the scaf-
folds. Therefore, 3 weeks may not be long enough for bone 
forming cells to migrate into the scaffolds to create bone tissue. 
Once the cells have migrated into the porous area of scaffolds, 
the existence of the mineral layer encouraged increased bone 
ingrowth at 10 weeks. The improvement of bone formation by 
biomineral coatings agreed with some of the previous studies 
performed using PLGA scaffolds in orthotopic sites [ 28 ] and 
PLGA microspheres in ectopic sites. [ 29 ] 
 Concentric ROI analysis of bone ingrowth suggests that 
coated scaffold base materials encouraged further penetra-
tion of bone interior to the scaffolds (Figure  5 b–d). The coated 
PLLA scaffolds had more bone ingrowth towards the outer 
edge compared with the coated PCL scaffolds, perhaps due 
to more initial mineral coating on the coated PLLA scaffolds 
than the coated PCL scaffolds. The coated PCL showed more 
bone formation deep inside of the scaffolds than the uncoated 
PCL scaffolds. Conversely, the coated PLLA scaffolds did not 
show signifi cant differences at the very inside of the scaffolds 
compared with the uncoated PLLA scaffolds. We speculate 
that this may be explained by inhibition of bone formation 
by PLLA degradation by-products, and slower degradation 
Adv. Healthcare Mater. 2015, 4, 621–632
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 Figure 6.  H&E histological staining of implanted PLLA and PCL scaffolds. PLLA and PCL materials were removed and became transparent in the images 
(indicated by @). Images show little bone ingrowth in the implanted PLLA scaffolds (a,b) and PCL scaffolds (e,f) at 3 weeks. Some blood-vessel-like 
tissues are observed in the coated PLLA (a) and PCL (e) scaffolds (green arrow), while more fi brous-like tissues are observed in the uncoated PLLA 
(b) and PCL (f) scaffolds. At 10 weeks, there is well-developed bone ingrowth containing marrow-like tissues in the coated PLLA scaffolds (c) and the 
coated PCL scaffolds (g), and more fi brous or fat-like tissues in the uncoated PLLA scaffolds (d) and the uncoated PCL scaffolds (h).
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of PCL, which may produce fewer by-products limiting bone 
formation. [ 15 ] 
 The cross-sections of the biomineral-coated scaffolds showed 
good bone contact on the biomineral coatings as well as more 
bone-like tissue formation, indicating that the biomineral coat-
ings supported direct bone formation rather than fi brous tissue 
formation (Figure  6 ,  7 ,  1 , Supporting Information). [ 26,27,29 ] Fur-
thermore, a signifi cant advantage of combining SFF with biomin-
eralization is demonstrated by regenerated bone completely pen-
etrating the connected regions throughout the porous scaffolds, 
something more diffi cult to attain with randomly connected salt-
leached scaffolds. [ 31 ] Thus, the designed and fully connected pore 
channels of SFF scaffolds likely allowed fl uid infi ltration into the 
center of the scaffolds to support complete biomineral coating (a 
fl uid mediated process) as well as tissue ingrowth. [ 6,8,9 ] 
 Despite the minimal effect of biomineral coatings on bone 
ingrowth at 3 weeks, the histological images show that coated 
scaffolds had more blood-vessel-like tissue containing bone 
marrow compared with the uncoated scaffolds (Figure  6 ). This 
may enhance the infi ltration of bone-forming cells in the scaf-
folds, which in part explains the increased bone ingrowth in 
the coated scaffolds at 10 weeks. The blood-vessel-like tissue in 
the coated scaffolds may also promote nutrient supply, leading 
to improved bone ingrowth throughout the scaffolds. As noted 
above, in an  ex vivo gene therapy approach like the one used in 
this study, large bony shells tend to form outside of the scaf-
folds preventing diffusion of nutrients into the center of the 
scaffolds. [ 50 ] This can also cause accumulation of degradation 
by-products inside the scaffolds, which could inhibit cell migra-
tion and tissue ingrowth. Since coated PLLA showed further 
bone ingrowth than uncoated PLLA scaffolds (Figure  5 ), having 
a biomineral coating on the scaffolds may also help counter 
these negative effects. [ 29 ] 
 Mechanical testing revealed the effect of the mineral coating 
process on the different materials (Figure  8 ). Although both 
PLLA and PCL scaffolds were treated with NaOH in the same 
manner to functionalize their surfaces for biomineral coating, 
only PLLA scaffolds had signifi cantly reduced mechanical 
properties, suggesting that PLLA degraded due to NaOH treat-
ment. [ 51 ] Elastic moduli of implanted scaffolds in this study 
tended to increase with longer implantation time due to increase 
of tissue mineral density, similar to our previous studies. [ 38,39,48 ] 
This increase was especially signifi cant for the coated PLLA scaf-
folds with advancing bone ingrowth compared with the uncoated 
PLLA whose porous area was fi lled with either fi brous or fat-like 
tissues. Although PLLA scaffolds degrade very slowly and main-
tain their architecture over 20 weeks, we have previously shown 
that this is a reduction in elastic modulus, mass, and molecular 
weight with longer implantation time in ectopic sites. [ 40 ] In con-
trast, there is not much difference between the  p values of the 
coated and uncoated PCL scaffolds. These data refl ect the fact 
that PLLA degrades much more rapidly than PCL, thus bone 
ingrowth in the PLLA scaffold more signifi cantly increases the 
degraded PLLA stiffness as compared to the intact PCL stiffness. 
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 Figure 7.  Cross-sectional images of implanted coated PLLA, uncoated PLLA, coated PCL, and uncoated PCL scaffolds at 3 and 10 weeks. Initial mineral 
coatings and regenerated bone tissues were seen on the coated PLLA scaffolds (a,e) and the coated PCL scaffolds (j,n). There was not clear integration 
of bone tissues into mineral coatings at 3 weeks (yellow box area (b,k)), while tissues had more bonding on minerals at 10 weeks (yellow box area, 
left (f,o) and right (g,p)). The arrows show that original mineral coating (solid orange arrow) and regenerated bone tissues (open orange arrow). The 
uncoated PLLA and PCL scaffolds showed trabecular-like tissues close to the scaffold surface (yellow box (d,m)) at 3 weeks, and lined bone tissue 
around the scaffold at 10 weeks (yellow box (i,r)). There are some spaces between the generated bone tissue (open green arrow) and the scaffold 
surface (solid green arrow).
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 Our results clearly support the conclusion that biomineral 
coating improves bone formation, which may be due to several 
possible mechanisms. The biomineral coating may increase 
hydrophilicity of PLLA and PCL scaffolds, increasing cell adhe-
sion, migration, and proliferation. [ 52–54 ] Calcium phosphate 
mineral has also been shown to increase protein adsorption, 
such as fi bronectin and vitronectin, which are important for 
bone cells to adhere on biomaterials and produce extracellular 
matrices. [ 55,56 ] Mineral coatings may also allow for local enrich-
ment of cell-secreted BMP-7 protein, as BMPs are known to 
interact strongly with biominerals, and the nanostructured 
biomineral coatings have a large surface area available for 
BMP binding and release. [ 44,57 ] In turn, this local enrichment of 
BMP-7 may have increased progression of osteogenesis in the 
mineral-coated scaffolds. Finally, release of calcium ions from 
biomineral coatings has been reported to promote cell prolif-
eration and differentiation and released calcium may have had 
a similar effect in our current study. [ 58 ] Further mechanistic 
studies will be required to more defi nitively delineate the mech-
anism behind the biomineral coating’s effects. 
 The results of this study are directly relevant to the concept 
of prefabricated bone fl aps, which are constructs placed in an 
ectopic site in to regenerate bone tissue in preparation for sur-
gical transfer to a bony site, for example to reconstruct complex 
craniofacial defects. However, examining biomineral-coated 
scaffolds in orthotopic sites is also important for the develop-
ment of clinically applicable scaffolds. 
 4.  Conclusion 
 This study examined the combination of computer-aided engi-
neered scaffolds and biomineral coatings using two biodegrad-
able materials to achieve bone ingrowth into porous scaffolds 
with identical architectures. SFF scaffolds made of PLLA and 
PCL were successfully coated with biomineral layers using 
the same mSBF procedures. The biomineral-coated scaffolds 
showed improved  in vivo bone formation, and the resulting 
bone tissue was fully connected and followed the scaffold pore 
architectures in contrast to the uncoated scaffolds that had lim-
ited bone ingrowth. 
 5.  Experimental Section 
 Porous Scaffold Design and Fabrication : Porous scaffolds 5 mm in 
diameter and 3 mm in height with 550 µm pore diameters were designed 
using image-based techniques and fabricated using the indirect SFF 
technique. [ 59,60 ] The resulting image representations were converted 
to stereolithography (STL) formats and sliced in Modelworks software 
(Solidscape, Inc., Merrimack, NH) to fabricate wax molds using a 
PatternMaster 3D printer (Solidscape, Inc., Merrimack, NH). These wax 
molds were cast into hydroxyapatite ceramic (HA) secondary molds. 
Polymer pellets, PLLA (Inherent Viscosity = 0.65 dL g −1 , Birmingham 
Polymers Inc., AL) and PCL (Molecular weight: 43 000–50 000; 
Polyscience Inc.), were heated at 205 °C and 120 °C, respectively, in 
a Tefl on mold in Lindberg/Blue M Vacuum Oven (Thermo Scientifi c, 
Asheville, NC). The HA molds were then placed into the Tefl on mold 
containing molten polymer under vacuum in order to force the polymer 
through the open pore network. The HA molds were then removed from 
the porous polymer scaffolds using RDO (APEX Engineering Products 
Corp, Plainfi eld, IL) and washed with 100% ethanol. 
 Mineral Coating Incubation in mSBF : Fabricated PLLA and PCL 
scaffolds were simultaneously coated in the same manner. [ 32 ] The 
scaffolds were hydrolyzed in a 0.1  M NaOH for 60 min at room 
temperature to expose carboxylate anions that serve as nucleation sites. 
After hydrolysis, the scaffolds were rinsed at least three times with 
deionized H 2 O. Each scaffold was incubated at 37 °C in 15 mL of mSBF 
for 14 d under continuous rotation. The mSBF solution had a similar 
composition to that of human plasma but with double the concentration 
of calcium and phosphate, and was prepared as previously reported. [ 20 ] 
Specifi cally, the following reagents were added to ddH 2 O heated to 37 °C 
in the order shown; 141 × 10 −3  M NaCl, 4.0 × 10 −3  M KCl, 0.5 × 10 −3  M 
MgSO 4 , 1.0 × 10 −3  M MgCl 2 , 4.2 × 10 −3  M NaHCO 3 , 20.0 × 10 −3  M Tris, 
5.0 × 10 −3  M CaCl 2 , and 2.0 × 10 −3  M KH 2 PO 4 . The solution was then 
adjusted to a fi nal pH of 6.8. The mSBF solution was renewed daily in 
order to maintain a consistent ionic strength throughout the experiment. 
 Figure 8.  Elastic moduli of the scaffolds with BMP-7-transduced HGFs 
(a) and with GFP-transduced HGFs (b) ( N = 5–6). The coated and 
uncoated PLLA scaffolds decreased their mechanical properties from 0 
to 3 weeks due to the degradation of polymers (indicated by # and +). 
The mechanical properties of the coated PLLA scaffolds increased sig-
nifi cantly from 3 to 10 weeks (indicated by ##), while the uncoated PLLA 
scaffolds did not have signifi cant increase (a). Both coated and uncoated 
PCL scaffolds showed a signifi cant (indicated by ##) or close to signifi -
cant increase of mechanical properties (a).
FU
LL
 P
A
P
ER
630 wileyonlinelibrary.com © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Adv. Healthcare Mater. 2015, 4, 621–632
www.advhealthmat.de
www.MaterialsViews.com
 Scaffold Surface Characterization : The surfaces of preimplanted 
scaffolds were examined in an environmental scanning electron 
microscope (ESEM), Philips XL30 ESEM. Imaging was performed in 
variable pressure mode at a pressure of 0.7 Torr and at an accelerating 
voltage of 10 kV. The coated scaffold surfaces were further investigated 
using SEM with XEDS. For XRD analysis, the mineral-coated scaffolds 
were immersed in chloroform (ACROS Organics) and stirred 
continuously for 20 min or until completely dissolved. The mixture was 
then centrifuged at 4000 rpm for 5 min to separate out the mineral 
component. The mineral was rinsed in fresh chloroform and centrifuged 
for a second time. After collecting the chloroform, the mineral powder 
was dried under the hood for 2 days to allow residual chloroform 
to evaporate for XRD analysis. XRD patterns were recorded using a 
general area detector diffraction system (GADDS), with a Hi-star 2-D 
area detector (20° < 2 θ < 40°) using Cu Kα radiation. The resulting 
patterns of the samples were identifi ed by computer matching with 
an International Centre for Diffraction Data (ICDD) powder diffraction 
database (ICDD card number for HA: 00–001–1008). 
 Scaffold Implantation in Mice Subcutaneous Sites : Primary HGFs 
were purchased (ScienCell, CA). HGFs were cultured and expanded 
on passage 6 near confl uence in Dulbecco's modifi cation of Eagles 
medium (DMEM) supplemented with 10% fetal bovine serum, and 
1% penicillin and streptomycin (Gibco). The HGFs were infected 
with AdCMV-BMP-7, a recombinant adenovirus construct expressing 
murine BMP-7 gene under a cytomegalovirus (CMV) promoter, or 
AdCMV-GFP, a recombinant adenovirus construct expressing murine 
GFP gene under a CMV promoter, at a multiplicity of infection (MOI) 
of 500 PFU/cell for 20 h. The scaffolds were sterilized in 70% ethanol, 
washed in Hank's Balanced Salt Solution (Life Technologies), and 
then in DMEM. 0.5 million cells were seeded into each scaffold by 
suspending them in 40 µL of 5 mg mL −1 collagen gel. The gelation 
procedure was as follows: Rat tail collagen high concentration (stock 
concentration = 9.03 mg mL −1 ; BD Bioscience Discovery Labs, San Jose, 
CA) were diluted with cold sterile 0.02 N acetic acid to make 5 mg mL −1 . 
As soon as 0.5 N sodium hydroxide with 220 mg mL −1 sodium 
bicarbonate to initiate gelation was added to Col I gel mixture, gel 
contents were mixed with cell and evenly resuspended. 40 µL of cell and 
gel mixture was placed in each hole of sterilized custom-made Tefl on 
mold, and the scaffolds were placed on top of gel to enforce infi ltration. 
This was followed by incubation at 37 °C for 40 min to solidify gels 
further. The scaffolds seeded with HGFs were transferred in ultra-low 
cluster 24-well plate (Corning Incorporated, NY) with DMEM containing 
2% FBS were incubated for 24 h on an orbital shaker. The scaffolds with 
the transduced HGFs were subcutaneously implanted into 6–7 week 
old (46–53 days’ old) female immunocompromised mice (NIHS-bg-
nu-xid, Harlan). After animals were anesthetized with an injection of 
ketamine/xylazine, 4 subcutaneous pockets were created and 4 scaffolds 
(one scaffold from each group) were implanted into each mouse. 
Scaffolds with BMP-7- and GFP-transduced HGFs were implanted into 
different animals. Finally surgical sites were closed with wound clips 
in compliance with University Committee on Use and Care of Animal 
(UCUCA) regulations. The mice were sacrifi ced at 3 and 10 weeks after 
the implantation, and the scaffold and tissue constructs were harvested, 
fi xed with Z-fi x (Anatech, Battle Creek, MI), and left in 70% ethanol for 
further assay. 
 Assay of Scaffolds, Regenerated Tissues, and Amount of Mineral Using 
µ-CT : All of the scaffolds preimplantation alone and post-implantation 
with tissue were scanned using a MS-130 high-resolution µ-CT Scanner 
(GE Medical Systems, Toronto, CAN) at a resolution of 16 µm. The 
scanned images were reconstructed using MicroView software (GE 
Healthcare). Each scan was calibrated with a calibration phantom 
containing air, water, and a material that mimics cortical bone. The 
calibration values of air and water were set to −1000 and 0 Hounsfi eld 
Units (HU), respectively, and the bone HU value was calculated using 
a standard conversion equation from air and water values. [ 61 ] The 
reconstructed images of the uncoated scaffold prior to implantation were 
used to calculate pore size, strut size, volume, and surface area, and the 
reconstructed images of all implanted scaffolds were used to calculate 
bone ingrowth into porous areas. For bone ingrowth calculations, a 
global region of interest (Global ROI) was selected with size of 5 mm 
diameter and 1.8 mm height located within the center of a scaffold, and 
then a threshold value, 1100 HU, was applied to calculate bone volume 
(BV) ( Figure  9 a). For further analysis of bone ingrowth, a concentric 
ROI (ConROI) was applied to both the 10 week data and preimplanted 
scaffolds by various outer diameters (O.D.) and inner diameters (I.D.) 
with the same height (1.8 mm), specifi cally denoted as ConROI-5 
(O.D. = 5 mm, I.D. = 4 mm), ConROI-4 (O.D. = 4 mm, I.D. = 3 mm), 
ConROI-3 (O.D. = 3 mm, I.D. = 2 mm), ConROI-2 (O.D. = 2 mm, I.D. = 
1 mm), ConROI-1 (O.D. = 1 mm, I.D. = 0 mm) (Figure  9 b). The bone 
ingrowth was determined by subtracting the amount of mineral in the 
ROI before implantation from the total amount of mineralized tissue after 
implantation ( N = 8).  To determine the amount of mineral on the scaffold 
surfaces, a cylindrical region of interest (ROI) with 5.6 mm diameter 
and 3.5 mm height was chosen to encompass the whole scaffold, and 
 Figure 9.  Global ROI was selected with size of 5 mm diameter and 1.8 mm height located within the center of a scaffold, and then a threshold value, 
1100, was applied to calculate bone volume (BV) (a). ConROI were applied to 10 weeks data and preimplanted scaffolds by various outer diameter 
(O.D.) and inner diameter (I.D.) with the same height (1.8 mm), ConROI-5 (O.D. = 5 mm, I.D. = 4 mm), ConROI-4 (O.D. = 4 mm, I.D. = 3 mm), 
ConROI-3 (O.D. = 3 mm, I.D. = 2 mm), ConROI-2 (O.D. = 2 mm, I.D. = 1 mm), ConROI-1 (O.D. = 1 mm, I.D. = 0 mm) (b). The bone ingrowth was 
determined by subtracting the amount of mineral in the ROI before implantation from the total amount of mineralized tissue after implantation.
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then the amount of mineral was calculated applying various threshold, 
600 HU, based on our previous studies ( N = 8). [ 32 ] 
 Mechanical Testing of Scaffolds with Regenerated Tissue : Following 
µ-CT scanning, compression tests were performed after scaffolds 
underwent a series of ethanol and were rehydrated in Milli-Q water 
for 30 min, using an MTS Alliance RT30 Electromechanical test frame 
(MTS Systems Corp., MN). The heights of the scaffolds were measured 
with a caliper. The cross-head speed was 1 mm min −1 after a preload 
of 0.227 kg (0.5 lbs). TestWorks4 software (MTS Systems Corp., MN) 
was used to record load and displacement data. The stress–strain 
curves were calculated from the initial dimensions of specimens. The 
compressive modulus was defi ned by the slope at the initial linear 
section of the stress–strain curve ( N = 5–6). 
 Histological Analysis : After µ-CT scanning, one harvested scaffold 
from each group was processed for histology. The scaffold and tissue 
constructs were demineralized with RDO and the residual polymer in 
the tissue was removed using chloroform prior to paraffi n-embedding. 
The scaffolds were then sectioned at the middle point at 5 µm and 
stained with hematoxylin and eosin (H&E) and Masson’s Trichrome. 
The implanted scaffolds without decalcifi cation or polymer removal were 
embedded in epoxy block (Embed 812, Electron Microscopy Sciences) 
and sectioned with microtome using a diamond blade (Isomet, Buehler, 
USA) to 200–300 µm thickness. [ 62 ] The cross sections were observed in 
backscattered electron imaging mode in a FEI Quanta focused ion beam 
workstation and environmental SEM, at a pressure of 0.5 Torr and at an 
accelerating voltage of 30 kV. 
 Statistical Analysis : Statistical analysis was performed with SPSS 
(SPSS, Inc., Chicago, IL USA). Two groups were analyzed with Student's 
 t -test for independent samples. Multiple comparison procedures were 
determined by one-way ANOVA followed by Tukey’s Post Hoc multiple 
comparisons. Standard deviation (SD) was reported in fi gures, and 
signifi cance was determined using a probability value of  p < 0.05.  
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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